Abstract:Bispecific antibodies represent a significant advancement in therapeutic antibody engineering, offering the ability to simultaneously target two distinct antigens. This dual-targeting capability enhances therapeutic efficacy, especially in complex diseases, such as cancer and autoimmune disorders, where drug resistance and incomplete target coverage are prevalent challenges. Bispecific antibodies facilitate immune cell engagement and disrupt multiple signaling pathways, providing a more comprehensive treatment approach than traditional monoclonal antibodies. However, the intricate structure of bispecific antibodies introduces unique pharmacokinetic challenges, including issues related to their absorption, distribution, metabolism, and excretion, which can significantly affect their efficacy and safety. This review provides an in-depth analysis of the structural design, mechanisms of action, and pharmacokinetics of the currently approved bispecific antibodies. It also highlights the engineering innovations that have been implemented to overcome these challenges, such as Fc modifications and advanced dimerization techniques, which enhance the stability and half-life of bispecific antibodies. Significant progress has been made in bispecific antibody technology; however, further research is necessary to broaden their clinical applications, enhance their safety profiles, and optimize their incorporation into combination therapies. Continuous advancements in this field are expected to enable bispecific antibodies to provide more precise and effective therapeutic strategies for a range of complex diseases, ultimately improving patient outcomes and advancing precision medicine.

Progress of Bispecific Antibody in Cancer Treatment

Immunotherapeutic progress and application of bispecific antibody in cancer

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Bispecific antibodies and their application in lung cancer treatment

Bispecific Antibodies As a Development Platform for New Concepts and Treatment Strategies

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

The State of the Art of Bispecific Antibodies for Treating Human Malignancies

Unlocking the potential of bispecific ADCs for targeted cancer therapy

Bispecific and multispecific antibodies in oncology: opportunities and challenges

The Application of the Drugs of Bispecific Antibodies in Anti-Tumor Therapy

Bispecific Antibodies Progression in Malignant Melanoma

Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape

Recent advances and challenges of bispecific antibodies in solid tumors

The present and future of bispecific antibodies for cancer therapy

Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Bispecific Antibody (bsab) Construct Formats and Their Application in Cancer Therapy.

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

Current status and future perspectives of bispecific antibodies in the treatment of lung cancer